You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Dexcel Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for DEXCEL PHARMA, and when can generic versions of DEXCEL PHARMA drugs launch?

DEXCEL PHARMA has two approved drugs.

There is one US patent protecting DEXCEL PHARMA drugs.

There are nine patent family members on DEXCEL PHARMA drugs in eight countries and six supplementary protection certificates in three countries.

Summary for Dexcel Pharma
International Patents:9
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Dexcel Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dexcel Pharma PERIOCHIP chlorhexidine gluconate TABLET;DENTAL 020774-001 May 15, 1998 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial
Dexcel Pharma OMEPRAZOLE omeprazole TABLET, DELAYED RELEASE;ORAL 022032-001 Dec 4, 2007 OTC Yes Yes 9,023,391 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Dexcel Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dexcel Pharma PERIOCHIP chlorhexidine gluconate TABLET;DENTAL 020774-001 May 15, 1998 5,002,769 ⤷  Try a Trial
Dexcel Pharma PERIOCHIP chlorhexidine gluconate TABLET;DENTAL 020774-001 May 15, 1998 5,023,082 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for DEXCEL PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Supplementary Protection Certificates for Dexcel Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 2011/016 Ireland ⤷  Try a Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0124495 SPC/GB01/006 United Kingdom ⤷  Try a Trial PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957 2012/048 Ireland ⤷  Try a Trial PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.